RNA interference (RNAi) induced by short interfering RNA (siRNA) allows for discovery research and large-scale screening [1] [2] [3] [4] [5] ; however, owing to their size and anionic charge, siRNAs do not readily enter cells 4, 5 . Current approaches do not deliver siRNAs into a high percentage of primary cells without cytotoxicity. Here we report an efficient siRNA delivery approach that uses a peptide transduction domain-doublestranded RNA-binding domain (PTD-DRBD) fusion protein.
DRBDs bind to siRNAs with high avidity, masking the siRNA's negative charge and allowing PTD-mediated cellular uptake. PTD-DRBD-delivered siRNA induced rapid RNAi in a large percentage of various primary and transformed cells, including T cells, human umbilical vein endothelial cells and human embryonic stem cells. We observed no cytotoxicity, minimal off-target transcriptional changes and no induction of innate immune responses. Thus, PTD-DRBD-mediated siRNA delivery allows efficient gene silencing in difficult-to-transfect primary cell types.
RNAi has become an important technology for manipulating cellular phenotypes, mapping genetic pathways and discovering therapeutic targets, and has therapeutic potential [1] [2] [3] [4] [5] . However, owing to their large size (B14,000 Da) and high negative charge, siRNAs do not readily enter cells 4, 5 . Indeed, naked siRNAs do not enter unperturbed cells even at millimolar concentrations 4 . Approaches for enhancing delivery of siRNAs to cells have included particle formation by means of cationic lipids, cholesterol, condensing polymers, antibody-protamine fusions and liposomes [1] [2] [3] [4] [5] . However, these approaches perform best with adherent tumor cells and do not work well with primary cells or nonadherent cell types, thereby severely limiting the cell types amenable to discovery research and large-scale screening with RNAi. Consequently, there is a need for an siRNA delivery approach that targets the entire cell population of all primary and tumorigenic cell types, is noncytotoxic and is independent of siRNA sequence.
In developing an siRNA delivery strategy, we started with cationic PTDs (also called cell-penetrating peptides), such as TAT, 8xArg
and Antp. Cationic PTDs have been shown to deliver a wide variety of cargo into primary cells and into most tissues in preclinical models, and are currently being tested in clinical trials 6 . They are rapidly taken up into cells by macropinocytosis, a form of fluid-phase uptake performed by all cells 7, 8 . Direct conjugation of cationic PTDs (6-8 positive charges) to anionic siRNAs (B40 negative charges) results in charge neutralization, inactivation of the PTD, aggregation/precipitation and cytotoxicity, with limited siRNA entry into the cells 9, 10 .
To circumvent PTD charge neutralization, we generated a TAT-PTD fusion protein with a single double-stranded (ds)RNA-binding domain (DRBD) [11] [12] [13] , which is known to bind siRNA with high avidity (K D B10 À9 ) 11 and thereby masks its negative charge. DRBDs are small, B65-residue domains that specifically bind B12-16 bp of the dsRNA backbone on 901 surface quadrants of the dsRNA helix, resulting in four DRBDs encompassing a single siRNA (Fig. 1a) ( Supplementary Fig. 1 online) .
To determine the ability of PTD-DRBD fusion proteins to deliver siRNAs, we generated a human H1299 lung adenocarcinoma reporter cell line using destabilized green fluorescent protein (dGFP) and destabilized red fluorescent protein (dDsRed) that allowed for direct determination of the magnitude of a single-cell RNAi response and hence, the percentage of cells undergoing an RNAi response. H1299 dGFP/dDsRed reporter cells were treated with PBS (mock), PTD-DRBD plus control siRNAs or PTD-DRBD plus one of two sequenceindependent GFP siRNAs (that is, two siRNAs with different sequences targeting the same mRNA; GFP1, GFP2) and analyzed by flow cytometry for GFP knockdown at 24 h (Fig. 1b, left panel) . PTD-DRBD delivery of GFP-specific siRNAs resulted in a substantial GFP knockdown with little to no alteration of the internal DsRed control. Similar RNAi responses were induced with three additional GFP siRNAs delivered by PTD-DRBDs (data not shown). None of the controls (nonspecific control siRNAs, PTD delivery peptide only) induced an RNAi response. PTD-DRBD-mediated GFP siRNA delivery also resulted in a substantially stronger RNAi response compared with lipofection-delivered siRNAs (Fig. 1b, right panel) . Notably, we detected little to no alteration of cell viability in PTD-DRBD: siRNA-treated cells, whereas lipofection resulted in varying levels of cytotoxicity ( Supplementary Fig. 2 online) . Single-cell flow cytometry analysis of PTD-DRBD:GFP siRNA-treated cells showed that the entire cellular population underwent a maximal RNAi response at 24 h that was maintained at 48 h (Fig. 1c,d ). In contrast, lipofectiondelivered siRNAs induced a partial RNAi response, with B20% of cells unresponsive (Fig. 1c,d) . Kinetic analysis over 8 d in dividing H1299 cells showed a slow decay of the RNAi response starting 3 d after PTD-DRBD:GFP siRNA treatment that was similar to the lipofection-mediated RNAi decay kinetics (Fig. 1e) . Similar results were obtained in primary human fibroblasts, keratinocytes, macrophages, and melanoma and glioma cells, containing integrated GFP reporter genes ( Supplementary Fig. 2 ). To circumvent the RNAi decay curve, we re-treated dividing H1299 cells on days 3 and 6 with PTD-DRBD:GFP siRNAs, resulting in maintenance of the extent and magnitude of the GFP RNAi response (Fig. 1f) .
We next targeted endogenous glyceraldehyde 3-phosphate dehydrogenase (GAPDH) mRNA by PTD-DRBD-mediated RNAi. Treatment of H1299 cells with one of two sequence-independent GAPDH siRNAs delivered by PTD-DRBD resulted in a GAPDH RNAi response that was first detected by qRT-PCR at 6 h after addition and reached a maximum by 12 h (Fig. 1g,h ). In contrast, none of the PTD-DRBD negative controls induced a GAPDH RNAi response. Notably, PTD-DRBD-mediated delivery of GAPDH1 siRNA resulted in a near-maximal RNAi response by 6 h, significantly (P o 0.001) earlier than control lipofection delivery of the same GAPDH siRNAs (Fig. 1g) , suggesting that PTD-DRBD-delivered siRNAs rapidly enter the cytoplasm and are loaded into the RNA-induced silencing complex. To determine whether PTD-DRBD-mediated siRNA delivery caused any cellular alterations, we examined the transcriptome of treated cells. Whole-genome microarrays were probed with total mRNA from PTD-DRBD GAPDH siRNA-treated H1299 cells at 12 h and 24 h (Fig. 1i) . Using a 1.6-fold increase/decrease filter of cellular mRNAs, we detected a dramatic reduction in the target GAPDH mRNA along with a limited number of both up-and downregulated genes. The upregulated genes were reduced in number and the magnitude of upregulation was close to the background variations of the signal (that is, o1.6Â levels) at 24 h, whereas the downregulated genes increased slightly in number and maintained a similar magnitude at 24 h (Fig. 1i) . None of these genes are present in an innate immune response pathway or congregate into a specific genetic pathway. In contrast, lipofection-treated cells showed both a dramatic increase in both the total number of genes altered and the magnitude of the increase (Fig. 1j) . In addition, the number of genes affected increased between 12 h and 24 h, suggesting that lipofection-based delivery substantially alters the transcriptome and may thereby confound interpretation of experimental outcomes. Lipofection induced interferon-regulated IFIT2 and IFIT3 genes. Moreover, lipofection-mediated GAPDH-specific knockdown was substantially smaller than PTD-DRBD-mediated knockdown. Taken together, these observations demonstrate that PTD-DRBD-mediated siRNA delivery efficiently targets the entire cellular population without cytotoxicity. Owing to inefficient siRNA delivery and cytotoxicity, RNAi manipulation of T cells remains problematic. Therefore, we focused on a cell type that is difficult to transfect with siRNAs, namely tumorigenic Jurkat T-cells. Jurkat T-cells containing an integrated GFP reporter gene were treated with GFP siRNA plus either PTD-DRBD or one of two lipofection reagents (Lipofection-2000 and RNAiMAX) at optimal concentrations and analyzed by flow cytometry for GFP knockdown at various time points (Fig. 2a) . PTD-DRBD delivery of GFP-specific siRNAs into Jurkat T-cells resulted in a strong GFP RNAi response in the entire population of Jurkat T-cells. In comparison, both lipofection reagents induced limited RNAi responses. Moreover, PTD-DRBD-delivered GAPDH siRNA resulted in a strong GAPDH RNAi response in Jurkat T-cells as measured by qRT-PCR, whereas the two lipofection reagents performed poorly (Fig. 2b) .
We next treated primary murine T cells with PTD-DRBD plus CD4-specific siRNAs and assayed for cellular levels of CD4 by flow cytometry (Fig. 2c, left panel) . The entire CD4 + cellular population had undergone an RNAi response at 24 h, whereas control siRNAs did not alter CD4 levels. Similarly, PTD-DRBD-mediated delivery of CD8-specific siRNAs into primary T cells resulted in a CD8-specific RNAi response with no change in CD4 levels (Fig. 2c, middle panel) . Consistent with these observations, we detected PTD-DRBD CD4-and CD8-specific RNAi responses by qRT-PCR at 12 and 24 h (P o 0.05) (Fig. 2d) . Notably, both flow cytometry and qRT-PCR analyses of internal control CD90 receptor showed little to no alteration in T cells treated with either PTD-DRBD CD4 or CD8 siRNA (Fig. 2c,d ). In contrast, we did not detect any RNAi responses in primary T cells using lipofection reagents (data not shown).
Primary human umbilical vein endothelial cells (HUVEC) are an important cell type for large scale RNAi screen; however, lipofection delivery of HUVECs results in both poor siRNA delivery and cytotoxicity. We targeted endogenous GAPDH mRNA by PTD-DRBD mediated RNAi. Consistent with the observations in H1299 cells above, treatment of primary HUVECs with one of the GAPDH siRNA (GAP1) delivered by PTD-DRBD resulted in a GAPDH RNAi response that reached a maximal RNAi response by 6 h (P o 0.01) (Fig. 2e) , while the other (GAP2) induced significant reduction in the GAPDH mRNA after 6 h ( P o 0.01) with a maximum after 12 h. In contrast, all PTD-DRBD negative controls failed to induce a GAPDH RNAi response. Notably, we detected little to no alteration of HUVEC cell viability in PTD-DRBD:siRNA treated cells compared to mock treated control cells (Fig. 2f) . By contrast, siRNAs delivered into HUVECs by lipofection induced significant cytotoxicity (Fig. 2f) .
Human embryonic stem (hES) cells have great potential to treat human disease 14 ; however, manipulation of hES cells with RNAi requires protocols that target the entire cell population in a noncytotoxic manner. We first tested the ability of PTD-DRBD to deliver siRNAs into H9 hES cells stably expressing GFP. PTD-DRBD-mediated delivery of GFP siRNAs induced a marked GFP RNAi response throughout the hES cell colony (Fig. 3a, circled area) . We next tested the ability of PTD-DRBD-mediated siRNA delivery to affect the fate of hES cells. The OCT4 (POU5F1) transcription factor is required to maintain hES cell pluripotency, and OCT4 RNAi knockdown results in hES cell cell-cycle exit and differentiation 14 . Treatment of HUES9 hES cells with PTD-DRBD plus OCT4 siRNA resulted in both an OCT4-specific knockdown followed by a reduced growth rate and cell cycle exit indicative of pluripotency loss and initiation of differentiation (Fig. 3b,c) . In contrast, neither mock treatment nor PTD-DRBD plus control siRNA altered hES cell cellular morphology, growth kinetics or OCT4 expression levels. Pluripotent hES cells express multiple cell surface markers, including stage-specific embryonic antigen-4 (SSEA-4) 15 . During differentiation into endoderm, hES cells decrease SSEA-4 expression, stop dividing, increase in size and subsequently express the GATA6 differentiation transcription factor 16 . PTD-DRBD-delivered OCT4 siRNA resulted in loss of OCT4 expression by day 2 with continued SSEA-4 expression (Fig. 3d) . However, by 10 d after treatment, OCT4 siRNA-treated cells had lost expression of SSEA-4 and induced expression of the endoderm-specific transcription factor GATA6 (Fig. 3e) . In contrast, hES cells mock treated or treated with PTD-DRBD plus control siRNAs did not differentiate or alter hES cell marker expression. Similar results were obtained by simultaneous PTD-DRBD-mediated knockdown of OCT4 and Nanog, another pluripotency-associated gene (data not shown). Taken together, these observations demonstrate the ability of PTD-DRBD to deliver siRNA and rapidly induce RNAi responses in three important and difficult-to-transfect cell types: T cells, HUVECs and hES cells.
RNAi has great potential to treat human disease, including nasal delivery to treat virus infection 17 ; however, in vivo siRNA delivery remains problematic [1] [2] [3] [4] [5] . To evaluate the potential of the PTD-DRBD fusion protein for in vivo applications, we assessed its immunogenicity in primary human peripheral blood mononuclear cells (PBMCs) and quantified the ability of PTD-DRBD to deliver siRNAs and induce an RNAi response in a reporter mouse model. siRNAs have been shown to stimulate activation of toll-like receptors 3, 7, 8 and induce innate immune responses 18 . However, PTD-DRBD-mediated delivery of immunostimulatory siRNAs did not activate interferon (IFN)-a or tumor necrosis factor (TNF)-a responses (in PBMCs) above background levels (Fig. 3f,g ).
We used transgenic ROSA26 mice expressing luciferase in the nasal and tracheal passages 19 to measure the efficiency of siRNA delivery by PTD-DRBD in vivo. After confirming luciferase expression by liveanimal imaging, the mice were randomly divided into groups (Fig. 3h,i) , treated intranasally with PBS, PTD-DRBD plus Luc siRNA or control siRNA and monitored daily for 15 d for luciferase expression. PBS and PTD-DRBD control siRNA-treated mice showed no change in luciferase expression over the course of the experiment. In contrast, PTD-DRBD-delivered Luc siRNA led to an extensive reduction of luciferase expression throughout the nasal and tracheal passages at day 1, which gradually recovered by day 15 (Fig. 3h,i ). These observations demonstrate the ability of PTD-DRBD-mediated siRNA delivery to induce a specific RNAi response to a quantifiable target protein in a reporter mouse model in vivo. siRNA delivery has become the rate-limiting barrier to efficient cell culture and preclinical and clinical usage of siRNA therapeutics [1] [2] [3] [4] [5] . Although current siRNA delivery approaches have merit, they generally do not target the entire population or even a high percentage of cells, especially primary cells, and often result in some degree of cytotoxicity and alterations in cell biology. In contrast, the PTD-DRBD siRNA delivery approach described here fulfills many of the criteria for an efficient siRNA delivery system for primary cells. PTD-DRBD delivered siRNAs and induced RNAi responses in the entire population of three difficult-to-transfect primary cell types (T cells, HUVECs and hES cells) rapidly and without cytotoxicity. Because DRBDs bind to dsRNAs (siRNAs) independent of sequence composition, PTD-DRBD could in theory deliver any siRNA into cells. Lastly, the intranasal knockdown of luciferase demonstrates the in vivo potential of PTD-DRBD-mediated siRNA delivery; however, more in vivo studies are needed to ascertain the full extent of in vivo utility. Thus, PTD-DRBD should prove useful for basic research, target screening and potential therapeutic applications.
METHODS
Methods and any associated references are available in the online version of the paper at http://www.nature.com/naturebiotechnology/.
Note: Supplementary information is available on the Nature Biotechnology website.
ONLINE METHODS
PTD-DRBD fusion protein construction, design and purification. pPTD-DRBD was constructed by PCR cloning of PKR DRBD-1 into a modified pTAT vector 8 resulting in TAT-TAT-HA-TAT-DRBD-6xHis ( Supplementary Fig. 1 ). The hemagglutinin (HA) epitope tag was used to follow the protein by immunoblot analysis and the 6xHis tag was used for purification over the first column, Ni-NTA. PTD-DRBD expression used BL21 codon plus (DH3) Escherichia coli (Stratagene); cells were transformed with pPTD-DRBD, cultured at 37 1C in Luria Bertani medium, then at 25 1C for 12 h after induction with 400 mM isopropyl-b-D-thiogalactoside. Cells were recovered by centrifugation for 5 min at 4,500g, sonicated in buffer A (20 mM HEPES (pH 7.5), 500 mM NaCl, 5 mg/ml aprotinin, 1 mg/ml leupeptin, 0.8 mM phenylmethylsulfonyl fluoride (PMSF)) plus 20 mM imidazole and soluble protein isolated by centrifugation for 15 min at 50,000g. PTD-DRBD was purified by passage over a Ni-NTA column (Qiagen), followed by loading onto a Mono-S AKAT FPLC in buffer B (50 mM HEPES (pH 7.5), 20 mM NaCl, 5% glycerol) and eluted in buffer C (buffer B plus 1.5 M NaCl). Purified PTD-DRBD was desalted (PD-10) into PBS-10% glycerol, and stored at -80 1C. EGFP-PEST (dGFP) or DsRed-PEST (dDsRed) lentiviruses were constructed using pCSC-SP-CW-EGFP-PEST or pCSC-SP-CW-DSRED 20 and pd2EGFP-N1-(destabilized GFP; BD Clontech) or pDsRed-Express-DR (destabilized DsRed; BD Clontech).
Cell culture conditions. H1299, HaCaT keratinocytes, HFF primary human fibroblasts and B16F0 melanoma cells were cultured in 10% FBS-DMEM, penicillin and streptomycin. T98G glioblastoma cells were cultured in 5% FBS-MEM and antibiotics. HUVEC cells were cultured in EGM-2 MV BulletKit (Lonza). Jurkat T-cells were cultured in 10% FBS-RPMI and antibiotics. THP-1 macrophage were grown in 10% FBS-RPMI plus 1 mM sodium pyruvate, 4.5 g/l glucose, 50 mM b-mercaptoethanol and antibiotics. Primary murine T cells were recovered from mouse spleens by MACS (Miltenyi Biotec), activated with antiCD3e antibody for 1 d and cultured in 10% FBS-RPMI plus 2 mM L-glutamine, 55 mM b-mercaptoethanol, 20 ng/ml IL2. The hES cell line HUES9 was kindly provided by D. Melton and H9 hES cells were obtained from WiCell. H9 hES cells were grown in 20% knockout serum-DMEM-F12 plus 55 mM b-mercaptoethanol, nonessential amino acids (NEAA), Gluta-Max, 4 ng/ml bFGF and antibiotics on murine fibroblast feeder layer. HUES9 hES cells were grown in HUES medium (10% knockout serum-DMEM plus 10% plasmonate, 55 mM b-mercaptoethanol, NEAA, Gluta-Max, 4 ng/ml bFGF, antibiotics) without murine fibroblast feeder layer in media preconditioned for 24 h on murine fibroblasts. Destabilized GFP (dGFP) and DsRed (dDsRed) proteins have B2 h and B12 h half-lives, respectively, substantially shorter than their wild-type parental proteins (424 h) and therefore were used as RNAi reporter targets. dGFP and dDsRed expressing cells were generated by infection with a lentivirus expressing Vesicular Stomatitis Virus Glycoprotein (VSVG) fused to dGFP or dsRED. VSVG-dGFP and/or VSVG-dDsRed infected cells were isolated by FACS.
